OMass Therapeutics appoints Birgitte Volck as Non-Executive Director
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Cantor Fitzgerald from $170.00 to $200.00. They now have an "overweight" rating on the stock.
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Ascendis Pharma A/S (NASDAQ: ASND) was given a new $180.00 price target on by analysts at Morgan Stanley.
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA [Yahoo! Finance]